Cigna is trading 4.2% down at $284.04 following its second-quarter 2026 earnings report as investors reassess margins and pharmacy-services headwinds.
- The company beat revenue and EPS expectations and raised its full-year adjusted EPS guidance to at least $30.45 per share.
- The decline appears driven by company-specific earnings positioning rather than macro pressure, as broader equity futures are trading higher this morning.